[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 8 sources · 1 days · First seen · Last updated

Ribociclib Natalee study breast cancer results

Overview

Long-term data from the Phase III Natalee study indicates that ribociclib (Kisqali), when combined with hormone therapy, reduces the risk of death by approximately 19% to 20% in patients with early-stage, HR-positive, HER2-negative breast cancer.

Presented at the 2026 European Society for Medical Oncology (ESMO) Congress, the findings show that survival benefits increased over the six-year observation period. Specifically, the absolute difference in overall survival rose from 1.2% at five years to 2.1% at six years. The study also noted improvements in invasive disease-free survival, which increased from 4.1% at five years to 5.3% at six years.

The research involved approximately 5,100 patients across 20 countries, focusing on high-risk patients in stages II and III. Experts noted that these results reinforce the long-term value of the combination therapy for this patient population.

Entities

Novartis · European Society for Medical Oncology · Michelino De Laurentiis · Madrid · Istituto Pascale

Timeline

  1. [HEALTH] 6 sources
    Ribociclib reduces early breast cancer death risk by 20% in 6-year study

    The Phase III Natalee study shows that combining ribociclib with endocrine therapy reduces the 6-year death risk by 20% for high-risk, early-stage HR+/HER2- breast cancer patients.

  2. [HEALTH] 2 sources
    Novartis Kisqali reduces early breast cancer mortality by 19%

    Novartis's Kisqali, combined with hormone therapy, reduced the risk of death by 19% in patients with specific early-stage breast cancers, according to long-term Phase III Natalee study data.

Sources

adnKronos.com · cash.ch · codirp.it · egnews.it · espressione24.it · it-boltwise.de · italpress.com · sbircialanotizia.it